Literature DB >> 2332449

Transcriptional regulation of DF3 gene expression in human MCF-7 breast carcinoma cells.

M Abe1, D Kufe.   

Abstract

The DF3 gene codes for a high molecular weight human breast tumor-associated glycoprotein. The detection of this antigen in human milk has also suggested that its expression represents a differentiated function of mammary epithelium. The present studies have examined the regulation of DF3 gene expression in human MCF-7 breast carcinoma cells. These cells express two DF3 transcripts of 4.5 and 7.0 kb. Treatment of MCF-7 cells with 12-0-tetradecanoylphorbol-13-acetate (TPA) was associated with increases in levels of both DF3 mRNAs. When nuclear run-on assays were used, DF3 gene transcription was at low to undetectable levels in untreated MCF-7 cells and was increased after TPA exposure. TPA-induced increases in DF3 mRNA levels were also inhibited by actinomycin D (ACT). MCF-7 cells exposed to ACT further demonstrated that the half-lives of the 4.5 and 7.0 kb transcripts are 26 and 11 h, respectively. The results also demonstrate that the protein synthesis inhibitor, cycloheximide (CHX), increases DF3 mRNA levels in MCF-7 cells. These effects of CHX were sensitive to actinomycin D and not associated with stabilization of the DF3 transcripts. Taken together, these findings indicate that DF3 gene expression is controlled at a transcriptional level in TPA- and CHX-treated MCF-7 cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2332449     DOI: 10.1002/jcp.1041430205

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  9 in total

1.  Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen.

Authors:  T Kurihara; D E Brough; I Kovesdi; D W Kufe
Journal:  J Clin Invest       Date:  2000-09       Impact factor: 14.808

Review 2.  Molecular chemotherapy for breast cancer.

Authors:  A Patterson; A L Harris
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

3.  Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter.

Authors:  L Chen; D Chen; Y Manome; Y Dong; H A Fine; D W Kufe
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

4.  MUC1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment.

Authors:  Sean P Pitroda; Nikolai N Khodarev; Michael A Beckett; Donald W Kufe; Ralph R Weichselbaum
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-16       Impact factor: 11.205

5.  Regulation of herpes simplex virus 1 replication using tumor-associated promoters.

Authors:  John T Mullen; Hideki Kasuya; Sam S Yoon; Nancy M Carroll; Timothy M Pawlik; Soundararajalu Chandrasekhar; Hideo Nakamura; James M Donahue; Kenneth K Tanabe
Journal:  Ann Surg       Date:  2002-10       Impact factor: 12.969

6.  Characterization of cis-acting elements regulating transcription of the human DF3 breast carcinoma-associated antigen (MUC1) gene.

Authors:  M Abe; D Kufe
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-01       Impact factor: 11.205

Review 7.  MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches.

Authors:  D W Kufe
Journal:  Oncogene       Date:  2012-05-14       Impact factor: 9.867

8.  Circulating levels and clinical implications of epithelial membrane antigen and cytokeratin-1 in women with breast cancer: can their ratio improve the results?

Authors:  Abdelfattah M Attallah; Mohamed El-Far; Mohamed M Omran; Sanaa O Abdallah; Mohamed A El-Desouky; Ibrahim El-Dosoky; Mohamed A Abdelrazek; Ahmed A Attallah; Mohamed A Elweresh; Gamal E Abdel Hameed; Hadil A Shawki; Karim S Salama; Ahmed M El-Waseef
Journal:  Tumour Biol       Date:  2014-07-30

Review 9.  Mucins in the mucosal barrier to infection.

Authors:  S K Linden; P Sutton; N G Karlsson; V Korolik; M A McGuckin
Journal:  Mucosal Immunol       Date:  2008-03-05       Impact factor: 7.313

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.